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Aims: Hypertensive patients develop cardiac hypertrophy and ﬁbrosis with increased stiffness, contractile
deﬁcit and altered perfusion. Angiotensin II (AngII) is an important factor in the promotion of this pathology.
The effects of AngII are partly mediated by endothelin-1 (ET-1) and transforming growth factor-β. The exact
feature of these pathways and the intercellular communications involved remain unclear. In this study, we
explored the role of endothelial cell-derived ET-1 in the development of AngII-induced cardiac ﬁbrosis and
hypertrophy.
Main methods:We used mice with vascular endothelial cell speciﬁc ET-1 deﬁciency (VEETKO) and their wild
type littermates (WT). Mice were infused for oneweekwith AngII (3.2 mg/kg/day, n=12) or vehicle (0.15 mol/
L NaCl and1 mmol/L acetic acid, n=5), using subcutaneousmini-pumps. Heartswere stainedwith hematoxylin–
eosin and masson's trichrome for histology. Cardiac gene expression and protein abundance were measured by
Northern Blot, real time PCR and Western Blot.
Key ﬁndings: AngII-induced cardiac hypertrophy, interstitial and perivascular ﬁbrosis were less pronounced in
VEETKO mice compared to WT. Blood pressure increased similarly in both genotypes. Expression of connective
tissue growth factor, tumor growth factor-β, collagen I and III in response to AngII required endothelial ET-1.
Endothelial ET-1 was also necessary to the elevation in protein kinase C δ abundance and ERK1/2 activation.
AngII-induced elevation in PKCε abundance was however ET-1 independent.
Signiﬁcance: This study underscores the signiﬁcance of ET-1 from the vasculature in the process of AngII-induced
cardiac hypertrophy and ﬁbrosis, independently from blood pressure. Endothelial ET-1 represents therefore a
possible pharmacological target.© 2012 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Hypertensive heart disease is a major health problem worldwide.
Patients develop cardiac hypertrophy and ﬁbrosis with increased
stiffness, contractile deﬁcit and altered perfusion.
The development of cardiac hypertrophy and ﬁbrosis is caused by
cardiac wall stress as well as by humoral and paracrine factors. Angioten-
sin II (AngII) has been recognized as a potent hypertrophic and ﬁbrotic
stimulus elevated in the overloaded heart (Gray et al., 1998; Holtz,
1993; Leask, 2010). The adverse cardiac effects of AngII are mediated
among others by endothelin-1 (ET-1) and transforming growth factor-β
(TGFβ) (Herizi et al., 1998; Schultz et al., 2002; Gonzalez et al., 2004).r Medicine, Department of In-
edicine, 7-5-1 Kusunoki-cho,
; fax: +81 78 382 5859.
).
Y-NC-ND license.The crucial involvement of cells adjacent to myocytes, particularly
ﬁbroblasts and vascular cells, toward cardiac hypertrophy has been
acknowledged before (Harada et al., 1997; Liu et al., 1999). In this
context, since ET-1 acts as a paracrine and autocrine factor rather
than an endocrine hormone, cardiac ET-1 may play an important
role in the manifestation of the AngII effects. In the heart, endothelial
cells (EC), cardiomyocytes and ﬁbroblasts are possible sources for ET-
1. Secretion of ET-1 by the ﬁbroblasts is induced by AngII and partic-
ipates in the hypertrophic feature of AngII on cardiomyocytes (Gray
et al., 1998; Harada et al., 1997). In the present study, the inﬂuence
of ET-1 from vascular endothelial origin on the development of
heart hypertrophy and ﬁbrosis associated with chronic infusion of
AngII was investigated. For that purpose, we used mice with speciﬁc
deletion of the ET-1 gene in vascular endothelial cells (VEETKO)
(Kisanuki et al., 2010). Additionally, we sought to analyze how differ-
ent mediators of the ﬁbrotic responses and actors of the signaling
cascades were regulated by endothelial ET-1 in response to AngII
infusion.
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Animals and experimental design
Experimental procedures were performed in accordance with the
guidelines for animal experimentation at Kobe University Graduate
School of Medicine. VEETKO mice and their WT littermates were
generated as previously described (Kisanuki et al., 2010). Twelve
week old males were divided into four groups: two groups (VEETKO,
n=12 andWT, n=13) were infused with 3.2 mg/kg/day AngII, while
two control groups (VEETKO, n=5 and WT, n=5) were treated with
vehicle (0.15 mol/L NaCl and 1 mmol/L acetic acid). Subcutaneous
implanted minipumps (Alzet model 2004) were used to deliver the
infusion. Systolic bloodpressure (SBP)wasmeasured by tail-cuffmethod
(Muramachi Kikai, Japan) in restrained awake mice before and after one
week AngII infusion. Average of at least 4 stable measurements was used
to determine the ﬁnal value. After a one-week infusion, the mice were
sacriﬁced and organs were withdrawn.Histology
Heart were embedded in tissue-freezing medium (Tissue-Tek OCT
compound) and stored at −80 °C. Sections of 5 μm were cut and
mounted on slides and subsequently stained with hematoxylin–eosin
and masson's trichrome. Photomicrographs at 400× magniﬁcation
were analyzed with the software ImageJ. Area of perivascular ﬁbrosis
was calculated as the ratio of the ﬁbrosis area surrounding the vessel
to the total vessel area. Myocardial interstitial ﬁbrosis was determined
as the area of stained connective tissue of a section divided by the
total tissue area of the section.Gene expression studies
Total RNA was extracted from the left ventricle using Isogen (Invitro-
gen) according to manufacturer's protocol. Northern blot analysis was
performed with [32P]-dCTP cDNA probes for transforming factor β
(TGFβ), connective tissue growth factor (CTGF), Collagen 1, Collagen 3,
atrial and brain natriuretic peptides (ANP and BNP) and standardized
with glyceraldehyde 3-phosphate dehydrogenase (GAPDH) probe. The
identity of the probe was conﬁrmed by DNA sequencing. The density of
the individual mRNA bands was measured using bioimaging analyzer
(BAS-2000; Fuji Photo Film, Tokyo, Japan). Quantitative RT-PCR of ET-1
was performed with 7500 ABI q-RTPCR system using Lux One-Step q-
RTPCR kit and primers (Invitrogen) according tomanufacturer's protocol.Table 1
Body weight (BW) and systolic blood pressure (SBP) before and after infusion and heart
weight/body weight ratio (HW/BW) after infusion of AngII for one week. mean±sem.Western Blot analysis
Total cardiac protein solution was subjected to SDS-polyacrylamide
gel electrophoresis and transferred to a nitrocellulose membrane.
Monoclonal antibodies were used to detect mouse PKCδ, PKCε (Santa
Cruz Biotechnology) and p-ERK 1/2 (Cell Signaling Technology).
Immunoblotting for α-tubulin was used as loading control.* pb0.05 vs. WT control; § pb0.05 vs. VEETKO control; # pb0.05 vs. WT AngII.
WT control VEETKO control WT AngII VEETKO AngII
n 5 5 13 12
Base line
BW (g) 24.4±0.6 25.0±0.4 26.0±0.4 26.0±0.9
SBP (mm Hg) 121±3 109±3* 119±2 108±2#
1 week infusion
BW (g) 24.4±0.6 25.0±0.5 26.2±0.7 24.9±0.9
HW/BW (mg/g) 4.9±0.2 4.8±0.2 6.5±0.2* 5.9±0.2§,#
SBP (mm Hg) 119±3 112±1* 142±2* 136±2§,#Statistical analysis
Continuous variables are presented as mean±SEM. Differences
were analyzed by one-way ANOVA with post-hoc comparisons by
Fischer's protected least signiﬁcant difference test for comparisons of
three or more groups and independent Student's t test for comparison
between two groups. A p value less than 0.05 was regarded as statisti-
cally signiﬁcant. Statistical analysis was performed with Statview 5.0
for Windows.Results
Baseline characteristics
At base line, body weight, gross cardiac anatomy, cardiac mass
(absolute and indexed to bodyweight), and structure of cardiacmuscle
ﬁbers were not different between the two genotypes. As previously
reported, systolic blood pressure of VEETKO mice was lower than in
WT littermates (109±3mm Hg vs. 121±3mm Hg, pb0.05; Table 1).
Unaltered hypertensive response following AngII infusion in VEETKO
mice
After one week of AngII infusion, SBP increased similarly in
VEETKO and WT mice and remained lower in VEETKO compared to
WT (136±2 mm Hg vs. 142±2 mm Hg, pb0.05). AngII-induced
elevation of SBP was not different between the two genotypes
(VEETKO: 28±1 mm Hg vs. WT: 23±4 mm Hg, p>0.05; Table 1).
Attenuated AngII-induced cardiac hypertrophy and ﬁbrosis in VEETKO
mice
AngII infusion for one week caused a marked cardiac hypertrophy
as indicated by approximately 35% increase in the heart weight to
body weight ratio of WT mice (4.768+0.218 vs. 6.493+0.208,
pb0.0001). The hypertrophic effect of AngII was also observed in
VEETKO mice, but to a lesser degree than WT mice i.e. 19.5%
(4.921±0.162 vs. 5.884±0.175, pb0.001). Thus, AngII-induced
cardiac hypertrophy was attenuated approximately 45% in VEETKO
mice (Table 1). No difference was observed in the interstitial and
perivascular ﬁbrosis of the left ventricle between vehicle-treated
WT and vehicle-treated VEETKO mice (data not shown). Following
AngII infusion the percentage of area of ﬁbrosis was 9.47±0.94%
and 6.03±0.88% in WT and VEETKO mice respectively (pb0.05).
Similarly, ﬁbrotic area surrounding the coronary arteries after
AngII infusion was markedly lower in VEETKO compared to WT
mice (0.83±0.03 in WT; 0.6±0.06 in VEETKO, pb0.05; Fig. 1).
Altered expression of the hypertrophic and ﬁbrotic mediators in VEETKO
mice
ET-1 gene expression in the left ventricle of VEETKOmice was half
as in WT littermate. AngII increased the expression of ET-1 in both
WT and VEETKO mice. ET-1 expression remained however higher in
WT mice (Fig. 2). AngII infusion induced an elevation of ANP and
BNP expression in both genotypes. In treated animals, both BNP and
ANP expression remained lower in VEETKO mice compared to WT
(Fig. 3). Collagen 1, collagen 3, TGFβ and CTGF mRNA expression
were all up regulated following AngII infusion. However, the expres-
sion of those genes remained lower in VEETKO mice (Fig. 4). In WT
mice, PKCδ, PKCε protein abundance and ERK 1/2 phosphorylation
Fig. 1. Cardiac interstitial and perivascular ﬁbrosis in WT and VEETKO mice after AngII infusion (Masson's trichrome staining). * pb0.05. n=4–5.
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abundance of PKCδ and ERK 1/2 activation, but not abundance of
PKCε, were markedly attenuated (Fig. 5).
Discussion
The conjoint role of AngII and ET-1 in the development of cardiac
ﬁbrosis and hypertrophy is well established. The intracellular signaling
pathways and the intercellular communications leading to these
processes in vivo remain however unclear. We report that ET-1 pro-
duced by endothelial cells is required for the complete AngII-induced
development of cardiac hypertrophy and ﬁbrosis. Given that blood
pressure increased similarly in both WT and VEETKO mice after AngII
infusion, we consider that the effect of endothelium-derived ET-1
reported here is independent from blood pressure. Moreover, the ET-
1-induced elevation of pro-ﬁbrotic and hypertrophic genes (TGF-β,
CTGF, Collagen 1 and 3) in response to AngII was mediated by PKCδ,
whereas AngII-induced PKCε activation remained ET-1 independent.
ET-1 secreted by cardiomyocytes contributes to the hypertrophic re-
sponse to AngII (Ito et al., 1993). In the same time, the release of growth
factors by non-myocyte cells is also required for the hypertrophy of
myocytes in response to mechanical and hormonal stimuli (vanFig. 2. Left ventricular expression of ET-1 of vehicle- and AngII-infusedWT and VEETKO
mice assessed by quantitative RT-PCR. *pb0.05. n=3–4.Wamel et al., 2002). Given the paracrine feature of ET-1 combined
with the fact that vascular endothelial cells are the major source of
ET-1, it is rational to propose that ET-1 from endothelial cells accounts
in part for the hypertrophy of cardiomyocytes. Moreover, cardiac remo-
deling is often accompanied by endothelial dysfunction (Liu et al.,
1999), which is characterized by the loss of balance in the production
of vasoactive substances, particularly NO and ET-1 (Gao et al., 2009).
In this situation, the endothelium no longer protects the heart (Liu et
al., 1999; Prasad et al., 2003).
VEETKO mice expressed half of the ET-1 amount compared to WT
in the aortic ventricle of the heart. AngII infusion increased ET-1 level
in both VEETKO and WT mice, which is reportedly provoked through
an endothelin receptor A (ETA) signaling (Fujisaki et al., 1995). In WT
mice, this increase was modest; previous experiments in the rat show
no increase of ET-1 peptide level in the myocardium after a similar
AngII infusion (Barton et al., 1998). Nevertheless, WT mice showed
still a higher ET-1 expression for about 25%. The ET-1 in the heart of
the VEETKOmice is only produced by cardiomyocytes and ﬁbroblasts,
while in WT mice endothelial cells are an additional source. These
different ET-1 levels affected AngII-induced heart hypertrophy as
well as ﬁbrosis.
Cardiac ﬁbrosis is the result of both hormonal and hemodynamic
stress. At baseline, VEETKO male mice were slightly hypotensive as
already reported before (Kisanuki et al., 2010). Oneweek after angioten-
sin II infusion, the systolic blood pressure remained signiﬁcantly higher
in WT mice than in VEETKO mice. The better outcome in VEETKO mice
could be therefore attributed to the lower blood pressure. The elevation
of blood pressure was however similar in both genotypes and
differences between the genotypes remained modest. Moreover, most
of the ET-1 remodeling effects are blood pressure independent. ET-1
transgenic overexpression in mice induces thus cardiac ﬁbrosis and
vascular dysfunction but not hypertension (Amiri et al., 2004; Schwarz
et al., 2002). We can therefore exclude the effect of blood pressure on
the role of ET-1 toward cardiac remodeling.
In the hypertrophic heart, the expression of ANP and BNP is elevated
and it is therefore considered as reliable prognosticmarkers (Shimojo et
al., 2006). It is established that the cardiac expression of natriuretic
peptides is under the control of ET-1 (Bianciotti and de Bold, 2000).
Our study showed that vascular endothelial ET-1 is responsible for
both ANP andBNP overexpression in thehypertrophic heart. At baseline
as well, the expression of ANP and BNP tended to be reduced, though
Fig. 3. Left ventricular expression of ANP and BNP of vehicle- and AngII-infused WT and VEETKO mice assessed by northern blot. *pb0.05. n=4–5.
Fig. 4. Left ventricular expression of TGFβ, CTGF, Collagen 1 and Collagen 3 of vehicle- and AngII-infused WT and VEETKO mice assessed by northern blot. *pb0.05, n=4–5.
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Fig. 5. Left ventricular protein expression of PKCδ, PKCε and p-ERK1/2 of vehicle- and AngII-infused WT and VEETKO mice assessed by Western Blot, *pb0.05, n=4–5.
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mention that elevation of natriuretic peptides in response to ET-1
after AngII stimulation is considered as a compensatory mechanism
because natriuretic peptides are anti-hypertrophic and anti-ﬁbrotic
particularly through the inhibition of ET-1 expression (Bianciotti and
de Bold, 2000; Fujisaki et al., 1995). In our setting, the level of ANP
and BNP correlates rather with the severity of hypertrophy and ﬁbrosis
probably because our set-up corresponds to an acute situation.
It is known that TGFβ is required for the cardiac hypertrophic effect
of AngII (Shimojo et al., 2006). The main sources of TGFβ are the ﬁbro-
blasts and the cardiomyocytes. TGFβ has been early recognized as a
communication agent between cardiomyocytes and endothelial cells
capable of stimulation of ET-1 expression (Nishida et al., 1993). Here,
we report that, the other way around, ET-1 from endothelial cells is
necessary for the complete AngII-induced elevation of TGFβ expression.
This observation conﬁrms the results of an in vitro study showing that
the hypertrophic effects of ET-1 on cardiomyocytes are mediated by
the TGFβ signaling pathway (Shimojo et al., 2006). Moreover, ET-1
from both ﬁbroblasts and endothelial cells may elevate TGFβ produc-
tion by cardiomyocytes (van Wamel et al., 2002). Our data show that
TGFβ mediates ET-1-induced hypertrophy in vivo and that ET-1 from
endothelial cells plays a role in this process. The importance of the
endothelial cells for the activation of the cardiac ﬁbroblasts has been
previously acknowledged with the use of diabetic VEETKO mice. In
these mice, ET-1 from endothelial cells is responsible in a paracrine
manner for the development of ﬁbrosis during diabetes (Widyantoro
et al., 2010). The present study proves that this is true also in a model
of cardiac hypertrophy in response to AngII.
Given that TGFβ is themain factor responsible forﬁbroblast activation,
the concomitant reduction of TGFβ expression and ﬁbrosis in the VEETKO
mice may indicate that vascular endothelial ET-1 impacts the ﬁbroblaststo myoﬁbroblasts transition. Moreover, in the context of diabetes induce
cardiac ﬁbrosis, endothelial ET-1 is responsible for elevation of TGFβ,
which promotes endothelial-to-mesenchymal transition and gives rise
to ﬁbroblasts (Widyantoro et al., 2010). Based on our data, we can only
speculate that this phenomenon, which strongly depends on TGFβ
(Zeisberg et al., 2007), occurs in our model.
Together with TGFβ, the expression of CTGF, a marker of activated
ﬁbroblast, was enhanced after AngII infusion but prevented in
VEETKO mice. CTGF is a matricellular protein which collaborates
with TGFβ in the induction of the ﬁbrotic response. The expression
of CTGF is promoted by AngII and ET-1. AngII is responsible for the
elevation of both CTGF and TGFβ expression in the hypertensive
and ﬁbrotic myocardium (Guo et al., 2006; Peng et al., 2003). In
cultured smooth muscle cells, AngII-induced expression of CTGF can
be partially prevented by an ETA antagonist, which indicates that
ET-1 contributes in CTGF upregulation caused by AngII (Rodriguez-
Vita et al., 2005). We have conﬁrmed this in vivo and further showed
that this is in part mediated by ET-1 from endothelial cells. In VEETKO
mice, the reduction of CTGF is not complete, which is in line with the
partial inhibition of AngII-induced CTGF expression in cells given an
endothelin antagonist (Rodriguez-Vita et al., 2005). In VEETKO mice,
both the inhibition of ET-1 and TGFβ may contribute to reduced
CTGF expression. Given that the upregulation of CTGF after an AngII in-
fusion is an early event and occurs before the stimulation of ﬁbrotic
genes such as collagen andﬁbronectin, CTGF is considered as amediator
of AngII (Ruperez et al., 2003). Nevertheless, ET-1 can directly enhance
CTGF expression. In vitro, ET-1 enhances CTGF independently of TGFβ
but co-incubation of ET-1 and TGFβ potentiates CTGF production
(Rodriguez-Vita et al., 2005). We further found that the abundance of
phosphorylated ERK1/2 is reduced in VEETKO mice. The activation of
ERK1/2 is required for the TGFβ-induced elevation of CTGF expression
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ET-1 from EC may act like a paracrine actor on the TGFβ/ERK1/2/CTGF
pathway. The inter-regulatory mechanisms between TGFβ and CTGF
upon matrix production seem complex: the expression of CTGF is
required for TGFβ mediated stimulation of collagen and ﬁbronectin
(Chujo et al., 2005). On the other hand, in mice carrying a transgene
coding for CTGF, cardiac ﬁbrosis is accompanied by an elevated TGFβ
expression (Yoon et al., 2010). Our study does not discriminatewhether
ET-1 impact directly CTGF expression or secondary through the activa-
tion of TGFβ.
PKCδ represents a common mediator of the ﬁbrotic response to
AngII, ET-1 and TGFβ in cardiac tissue (Chintalgattu and Katwa, 2009,
2004). In response to AngII, the activated PKCδ phosphorylates ERK1/
2, which further propagates the ﬁbrotic signal (Olson et al., 2008). We
observed an elevated PKCδ level in AngII treated WT, but not in the
VEETKO mice. These data suggest that PKCδ is a downstream mediator
of the ET-1 pathway when activated by AngII. This was conﬁrmed by
the similar ERK1/2 activation pattern observed between the groups,
since ERK1/2 is a target of PKCδ (Heidkamp et al., 2001).
In our setting, AngII elevated the abundance of PKCε. This observation
is in line with previous in vitro study demonstrating that PKCε partici-
pates in the activation of ﬁbroblast induced by AngII (Stawowy et al.,
2005). The speciﬁc blockade of PKCε prevents the development of ﬁbro-
sis in the heart of hypertensive rats (Inagaki et al., 2008). On the other
hand, PKCε deﬁcient mice develop cardiac ﬁbrosis (Klein et al., 2005).
In VEETKO mice, the expression of PKCε seems to be uncoupled from
the level of ﬁbrosis. Our study can unfortunately not clarify the role of
PKCε toward ﬁbrosis and can only conﬁrm that it is upregulated in
response to AngII stimulus. Nevertheless, in both VEETKO and WT
mice, heart weight was higher after AngII infusion and in both genotypes
the abundance of PKCε was elevated. These results are in accordance
with the cardiac hypertrophic role of PKCε observed in many murine
models (Ferreira et al., 2010). This feature seems to be ET-1 independent
because AngII-induced PKCε elevation was similar in VEETKO and WT
mice. Nevertheless, in addition to regulation at the expression level, ET-
1 controls the activity of PKC. The activation of PKC by ET-1 is complex
and involves in particular phosphorylation and translocation (Markou
et al., 2006; Pucéat et al., 1994). This level of regulation should be taken
in consideration.
Reactive oxygen species may play an important role in AngII and
ET-1 induced cardiac hypertrophy. Both AngII and ET-1 activate the
NADPH oxidase in the heart (Kimura et al., 2005; Zeng et al., 2008).
The consecutive increase in ROS can stimulate the hypertrophic
MAP kinase cascade (Essick et al., 2011). We have shown that the
increased level of ERK1/2 phosphorylation due to AngII infusion was
prevented in VEETKO mice compared to WT. Whether endothelium-
derived ET-1 activation of ERK1/2 is due to an enhanced ROS activa-
tion remains open.
Based on the data presented here, it is difﬁcult to distinguish
between the autocrine and paracrine effects of ET-1 on the expression
level of the different factors (TGFβ, CTGF). The endothelin receptors,
particularly ETA, present on ﬁbroblasts are known to play a role in
the development of ﬁbrosis (Gray et al., 1998; Peng et al., 2003).
The presence of ETA on myocytes seems to be not required for AngII-
induced cardiac ﬁbrosis in mice (Kedzierski et al., 2003), which would
indicate that the mediators of the ET-1 response are produced rather
by endothelial cells and ﬁbroblasts and affect secondary the myocytes.
Conclusion
This study underscores the signiﬁcance of the paracrine effect of
the vasculature in the process of AngII-induced cardiac hypertrophy.
Among other vascular mediators, ET-1 produced by the endothelial
cells may play a predominant role in the development of cardiac
hypertrophy and ﬁbrosis. Even though systemic blockade of ET-1
failed to improve prognosis of heart failure patients, speciﬁcallytargeting endothelial cells ET-1 may be a powerful tool to treat the
so far incurable cardiac ﬁbrotic condition.
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